Genedrive - Capital Network: Ready to launch the first point-of-care HepC test
genedrive (GDR.LON), an emerging UK medtech company, focuses on the development and commercialization of an innovative, point-of-care diagnostic system, also called Genedrive® (in this report, "genedrive" (GDR.LON) refers to the company, whereas "Genedrive®" indicates the product). genedrive (GDR.LON) is poised to become the first company to launch a decentralized Hepatitis C diagnostic, entering a large market at a time when new curative therapies for the disease are transforming opportunities for testing and treatment. A Genedrive® TB diagnostic has already been launched and the platform has a wide range of alternative applications.
In the coming months we expect genedrive to update the market on several key fronts:
• CE mark for the HepC Genedrive® system expected by mid-2017
• Distribution agreements for the commercialization of the HepC device in high burden countries
• Launch of Genedrive® for the diagnosis of HepC
• Next steps for Genedrive® development in other diseases
• Ongoing strategic reassessment of their legacy CRO business
Quick facts: Genedrive PLC
Market Cap: £6.15 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE